PACOME (PAtient Cancer Oral MEdication) Cohort of Patients Treated with Oral Anticancer Drugs Benefiting from Oncoral Multidisciplinary Monitoring in Real Life: Predictive Factors and Safety of Treatments

Launched by HOSPICES CIVILS DE LYON · Mar 12, 2024

Keywords

ClinConnect Summary

The PACOME clinical trial is focused on understanding how patients with cancer are treated with oral anticancer drugs (ATCO) in everyday life. Many patients prefer taking these medications at home instead of visiting the hospital for injections, which gives them more freedom and comfort. However, managing these treatments outside of a hospital can lead to mistakes or issues with the medications, which might affect how well the treatment works. The goal of this study is to gather information about patients using the Oncoral program, which provides careful support and monitoring from a team of healthcare professionals, including doctors, pharmacists, and nurses. By collecting data on patients' experiences, the trial aims to improve the care and safety of oral cancer treatments.

To be eligible for this study, participants must be over 18 years old, scheduled to start treatment with an oral anticancer drug, and being followed up at specific departments in Lyon-Sud hospital. They should not have any significant mental health issues that would interfere with the study. Participants can expect to share information about their health, quality of life, and experiences with their treatment. This trial is not yet recruiting participants, but it will help create a better understanding of how to support cancer patients who are using oral medications in their everyday lives.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • aged over 18
• • eligible for treatment with oral anticancer drug (ATCO) (excluding clinical trial) in a cancer indication and whose treatment with an oral anticancer drug is scheduled
• • follow-up in one of the following departments at Lyon-Sud hospital: pulmonology, dermatology, hematology, medical oncology, gastroenterology or radiotherapy.
• • without a major psychiatric disorder likely to hinder the progress of the study, in the opinion of the investigator
• • participant in the ONCORAL monitoring program
• • Not having opposed participating in the study
• Exclusion Criteria:
• • in an institution
• • under legal protection measure